We are live on ! Find out more
IFRX icon

InflaRx

42 hedge funds and large institutions have $56.4M invested in InflaRx in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

219% more capital invested

Capital invested by funds: $17.7M → $56.4M (+$38.7M)

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

41.9% more ownership

Funds ownership: 13.46%55.36% (+42%)

27% more funds holding

Funds holding: 3342 (+9)

64% less call options, than puts

Call options by funds: $49K | Put options by funds: $135K

Holders
42
Holders Change
+9
Holders Change %
+27.27%
% of All Funds
0.74%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
12
Reduced
7
Closed
9
Calls
$49K
Puts
$135K
Net Calls
-$86K
Net Calls Change
-$335K

IFRX Hedge Fund Activity: Q1 2021 in Review

42 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q1 2021, worth a combined $56.4M — up 219% from $17.7M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new IFRX positions and 9 closed out — a net gain of 9 holders — while 12 added to existing stakes and 7 trimmed.

The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $16.8M. The largest seller was Baker Bros. Advisors, cutting an estimated $3.68M.

  • 42 institutional investors held InflaRx (IFRX) as of Q1 2021, up from 33 in Q4 2020.
  • Funds reported $56.4M of InflaRx stock for Q1 2021, up 219% quarter-over-quarter.
  • 18 funds opened new InflaRx positions in Q1 2021 and 9 closed out, a net change of +9 holders.
  • The largest InflaRx buyer in Q1 2021 was Suvretta Capital Management, an estimated $16.8M added.
  • The largest InflaRx seller in Q1 2021 was Baker Bros. Advisors, an estimated $3.68M sold.

Based on aggregated 13F filings for Q1 2021.